KRAS and cancer: These strategies can also be combined, as bispecific antibodies that cross‐link HLA‐A*02:01 presenting ARS1620‐modified epitope to CD3+ T cells could induce cancer cell killing even of cancer cells resistant to direct KRAS G12C inhibition.107